Fan Z, Aman Y, Ahmed I, Chetelat G, Landeau B, Ray Chaudhuri K, Brooks DJ, Edison P (2014) Influence of microglial activation on neuronal function in Alzheimers and Parkinsons disease dementia
M., Gallant, C., Gangopadhyay, S
10.1002/jsfa.4465 55 Godoy de LimaR.BarrosM
b , Table of apparent MichaelisMenten parameters
Side Effects: Sedation Parkinsonism symptoms QT prolongation (may be significant if taking with drugs inhibiting CYP3A4/5 or 2D6) Pharmacokinetics: undergoes rapid hepatic metabolism involving carbonyl reductase and CYP2D6 to 2 deuterated active metabolites -dihydrotetrabenazine (-HTBZ) and -dihydrotetrabenazine (-HTBZ), with eventual renal elimination of metabolites the -HTBZ and -HTBZ metabolites are primarily responsible for the pharmacological & therapeutic effects produced by the parent prodrug twice a day dosing effect half life 9.4 hours (Schneider et al, 2021) HT: Resistant Hypertension
Human clinical trials are limited (fewer than 10 exist) and none have tracked use beyond 12 weeks
